Are macrolides as effective as fluoroquinolones in Legionella pneumonia?: YES, But...
Legionella pneumonia (LP) is a well-known cause of community-acquired pneumonia (CAP) in immunocompetent patients. This intracellular pathogen is considered one of the "core microorganisms" of CAP and it is also a microorganism that can cause hospital-acquired pneumonia (HAP) either in ind...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión aceptada para publicación |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:2445/164343 |
| Acceso en línea: | https://hdl.handle.net/2445/164343 |
| Access Level: | acceso abierto |
| Palabra clave: | Antibiòtics Pneumònia adquirida a la comunitat Pneumònia Infeccions nosocomials Legionel·la Antibiotics Community-acquired pneumonia Pneumonia Nosocomial infections Legionella |
| Sumario: | Legionella pneumonia (LP) is a well-known cause of community-acquired pneumonia (CAP) in immunocompetent patients. This intracellular pathogen is considered one of the "core microorganisms" of CAP and it is also a microorganism that can cause hospital-acquired pneumonia (HAP) either in individual cases or in the form of large-scale outbreaks. Immunosuppressed patients have a higher risk of acquiring this infection, both in the community and in the hospital, for this reason LP has to be empirically covered and intensively searched for diagnosis. Inadequate initial or delayed antibiotic treatments in LP are factors associated with a worse prognosis. |
|---|